NCT07090161招募中2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 240
- 试验地点
- 28
- 主要终点
- Change from baseline to treatment week 4 in SiSBP
研究概览
简要总结
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies
排除标准
- •Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency
研究组 & 干预措施
Experimental/Iloperidone
Experimental
干预措施: iloperidone (Drug)
Placebo Comparator
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline to treatment week 4 in SiSBP
时间窗: screening to treatment week 4
次要结局
未报告次要终点
研究者
研究点 (28)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart FailureCardiac-induced EdemaNCT01618448Taiwan Otsuka Pharm. Co., Ltd85
已完成
2 期
Efficacy of SENS-111 in Patients Suffering From Acute Unilateral VestibulopathyAcute Unilateral Vestibulopathy (AUV)NCT03110458Sensorion107
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 PreventionCOVID-19NCT05305560MedinCell S.A400
已完成
4 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 'Ursa Complex Soft Cap. (UDCA-004)' in Patients With Physical Fatigue.FatigueNCT02418130Daewoong Pharmaceutical Co. LTD.166
已完成
2 期
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD SubjectsAlzheimer DiseaseNCT04251182T3D Therapeutics, Inc.250